<SEC-DOCUMENT>0000875320-23-000010.txt : 20230501
<SEC-HEADER>0000875320-23-000010.hdr.sgml : 20230501
<ACCEPTANCE-DATETIME>20230501160827
ACCESSION NUMBER:		0000875320-23-000010
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		13
CONFORMED PERIOD OF REPORT:	20230501
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20230501
DATE AS OF CHANGE:		20230501

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			VERTEX PHARMACEUTICALS INC / MA
		CENTRAL INDEX KEY:			0000875320
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				043039129
		STATE OF INCORPORATION:			MA
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-19319
		FILM NUMBER:		23873651

	BUSINESS ADDRESS:	
		STREET 1:		50 NORTHERN AVENUE
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02210
		BUSINESS PHONE:		6173416393

	MAIL ADDRESS:	
		STREET 1:		50 NORTHERN AVENUE
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02210
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>vrtx-20230501.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2023 Workiva--><!--r:39b77e58-d50b-4e87-a966-5773b7766a3f,g:48973149-c2d4-4722-94fe-ccce81753841,d:84363f41ee6b472a9777c3b66bcfa26a--><html xmlns="http://www.w3.org/1999/xhtml" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>vrtx-20230501</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i1dbad092e05447cbbaec99507aa54883_D20230501-20230501" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjg0MzYzZjQxZWU2YjQ3MmE5Nzc3YzNiNjZiY2ZhMjZhL3NlYzo4NDM2M2Y0MWVlNmI0NzJhOTc3N2MzYjY2YmNmYTI2YV8xMy9mcmFnOjUyMjhmMTQyYWIxYTRiNTdiODhhMjE3YmIzYWM5YmMxL3RhYmxlOjM4MTFkMTE1NjlmYjQ2Y2JhMjg5NzA4YmU3OTFiZjI3L3RhYmxlcmFuZ2U6MzgxMWQxMTU2OWZiNDZjYmEyODk3MDhiZTc5MWJmMjdfMi0xLTEtMS0xNTQ1MTA_c5b55de1-b824-4256-9b44-92857cabf57f">0000875320</ix:nonNumeric><ix:nonNumeric contextRef="i1dbad092e05447cbbaec99507aa54883_D20230501-20230501" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjg0MzYzZjQxZWU2YjQ3MmE5Nzc3YzNiNjZiY2ZhMjZhL3NlYzo4NDM2M2Y0MWVlNmI0NzJhOTc3N2MzYjY2YmNmYTI2YV8xMy9mcmFnOjUyMjhmMTQyYWIxYTRiNTdiODhhMjE3YmIzYWM5YmMxL3RhYmxlOjM4MTFkMTE1NjlmYjQ2Y2JhMjg5NzA4YmU3OTFiZjI3L3RhYmxlcmFuZ2U6MzgxMWQxMTU2OWZiNDZjYmEyODk3MDhiZTc5MWJmMjdfMy0xLTEtMS0xNTQ1MTA_f54643c8-a5b1-44f6-8811-3a57783383cd">VERTEX PHARMACEUTICALS INC / MA</ix:nonNumeric><ix:nonNumeric contextRef="i1dbad092e05447cbbaec99507aa54883_D20230501-20230501" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjg0MzYzZjQxZWU2YjQ3MmE5Nzc3YzNiNjZiY2ZhMjZhL3NlYzo4NDM2M2Y0MWVlNmI0NzJhOTc3N2MzYjY2YmNmYTI2YV8xMy9mcmFnOjUyMjhmMTQyYWIxYTRiNTdiODhhMjE3YmIzYWM5YmMxL3RhYmxlOjM4MTFkMTE1NjlmYjQ2Y2JhMjg5NzA4YmU3OTFiZjI3L3RhYmxlcmFuZ2U6MzgxMWQxMTU2OWZiNDZjYmEyODk3MDhiZTc5MWJmMjdfNi0xLTEtMS0xNTQ1MTA_5c916cd9-b16a-4eda-9f74-e76658da6afb">false</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="vrtx-20230501.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i1dbad092e05447cbbaec99507aa54883_D20230501-20230501"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875320</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-01</xbrli:startDate><xbrli:endDate>2023-05-01</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i84363f41ee6b472a9777c3b66bcfa26a_1"></div><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="margin-bottom:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:232%">FORM <ix:nonNumeric contextRef="i1dbad092e05447cbbaec99507aa54883_D20230501-20230501" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjg0MzYzZjQxZWU2YjQ3MmE5Nzc3YzNiNjZiY2ZhMjZhL3NlYzo4NDM2M2Y0MWVlNmI0NzJhOTc3N2MzYjY2YmNmYTI2YV8xL2ZyYWc6ODVkYmExZWRmOTM0NDBlOTlmNjU5NDhmYTdkOGZkOTMvdGV4dHJlZ2lvbjo4NWRiYTFlZGY5MzQ0MGU5OWY2NTk0OGZhN2Q4ZmQ5M18xNjE5_5448ecc1-ebb0-4c94-9360-49f74a92a785">8-K</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Date of Report (Date of earliest event reported) <ix:nonNumeric contextRef="i1dbad092e05447cbbaec99507aa54883_D20230501-20230501" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjg0MzYzZjQxZWU2YjQ3MmE5Nzc3YzNiNjZiY2ZhMjZhL3NlYzo4NDM2M2Y0MWVlNmI0NzJhOTc3N2MzYjY2YmNmYTI2YV8xL2ZyYWc6ODVkYmExZWRmOTM0NDBlOTlmNjU5NDhmYTdkOGZkOTMvdGV4dHJlZ2lvbjo4NWRiYTFlZGY5MzQ0MGU5OWY2NTk0OGZhN2Q4ZmQ5M18yMjU_3f5b0cb7-f870-4852-bd87-a372cb953bcf">May 1, 2023</ix:nonNumeric> </span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:144%">Vertex Pharmaceuticals Incorporated </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:144%">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i1dbad092e05447cbbaec99507aa54883_D20230501-20230501" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjg0MzYzZjQxZWU2YjQ3MmE5Nzc3YzNiNjZiY2ZhMjZhL3NlYzo4NDM2M2Y0MWVlNmI0NzJhOTc3N2MzYjY2YmNmYTI2YV8xL2ZyYWc6ODVkYmExZWRmOTM0NDBlOTlmNjU5NDhmYTdkOGZkOTMvdGFibGU6OTJkN2UwMmExMWM0NGY4MThhNWEyMDE4MzgzOTViN2QvdGFibGVyYW5nZTo5MmQ3ZTAyYTExYzQ0ZjgxOGE1YTIwMTgzODM5NWI3ZF8wLTAtMS0xLTE1NDUxMA_cc3626ee-16e2-4885-843d-8c23d1f1b08d">Massachusetts</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:144%"><ix:nonNumeric contextRef="i1dbad092e05447cbbaec99507aa54883_D20230501-20230501" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjg0MzYzZjQxZWU2YjQ3MmE5Nzc3YzNiNjZiY2ZhMjZhL3NlYzo4NDM2M2Y0MWVlNmI0NzJhOTc3N2MzYjY2YmNmYTI2YV8xL2ZyYWc6ODVkYmExZWRmOTM0NDBlOTlmNjU5NDhmYTdkOGZkOTMvdGFibGU6OTJkN2UwMmExMWM0NGY4MThhNWEyMDE4MzgzOTViN2QvdGFibGVyYW5nZTo5MmQ3ZTAyYTExYzQ0ZjgxOGE1YTIwMTgzODM5NWI3ZF8wLTEtMS0xLTE1NDUxMA_70125e48-db21-48bd-a116-b6ae383615ad">000-19319</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i1dbad092e05447cbbaec99507aa54883_D20230501-20230501" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjg0MzYzZjQxZWU2YjQ3MmE5Nzc3YzNiNjZiY2ZhMjZhL3NlYzo4NDM2M2Y0MWVlNmI0NzJhOTc3N2MzYjY2YmNmYTI2YV8xL2ZyYWc6ODVkYmExZWRmOTM0NDBlOTlmNjU5NDhmYTdkOGZkOTMvdGFibGU6OTJkN2UwMmExMWM0NGY4MThhNWEyMDE4MzgzOTViN2QvdGFibGVyYW5nZTo5MmQ3ZTAyYTExYzQ0ZjgxOGE1YTIwMTgzODM5NWI3ZF8wLTItMS0xLTE1NDUxMA_0aa8d63e-b598-4dbc-a8e0-fc379975dfc7">04-3039129</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(State or other jurisdiction of incorporation)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(Commission File Number)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(I.R.S. Employer Identification No.)</span></div></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:144%"><ix:nonNumeric contextRef="i1dbad092e05447cbbaec99507aa54883_D20230501-20230501" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjg0MzYzZjQxZWU2YjQ3MmE5Nzc3YzNiNjZiY2ZhMjZhL3NlYzo4NDM2M2Y0MWVlNmI0NzJhOTc3N2MzYjY2YmNmYTI2YV8xL2ZyYWc6ODVkYmExZWRmOTM0NDBlOTlmNjU5NDhmYTdkOGZkOTMvdGV4dHJlZ2lvbjo4NWRiYTFlZGY5MzQ0MGU5OWY2NTk0OGZhN2Q4ZmQ5M18xNjI2_6d41c32a-cc43-4dca-8ccc-23926ee1e094">50 Northern Avenue</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:144%"><ix:nonNumeric contextRef="i1dbad092e05447cbbaec99507aa54883_D20230501-20230501" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjg0MzYzZjQxZWU2YjQ3MmE5Nzc3YzNiNjZiY2ZhMjZhL3NlYzo4NDM2M2Y0MWVlNmI0NzJhOTc3N2MzYjY2YmNmYTI2YV8xL2ZyYWc6ODVkYmExZWRmOTM0NDBlOTlmNjU5NDhmYTdkOGZkOTMvdGV4dHJlZ2lvbjo4NWRiYTFlZGY5MzQ0MGU5OWY2NTk0OGZhN2Q4ZmQ5M18xNjIw_d3eda62c-25af-4d29-9eae-788da80b847f">Boston</ix:nonNumeric>, <ix:nonNumeric contextRef="i1dbad092e05447cbbaec99507aa54883_D20230501-20230501" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjg0MzYzZjQxZWU2YjQ3MmE5Nzc3YzNiNjZiY2ZhMjZhL3NlYzo4NDM2M2Y0MWVlNmI0NzJhOTc3N2MzYjY2YmNmYTI2YV8xL2ZyYWc6ODVkYmExZWRmOTM0NDBlOTlmNjU5NDhmYTdkOGZkOTMvdGV4dHJlZ2lvbjo4NWRiYTFlZGY5MzQ0MGU5OWY2NTk0OGZhN2Q4ZmQ5M18xNjI3_ec8c6ad3-15fc-4460-b9dc-33ce030f1349">Massachusetts</ix:nonNumeric>  <ix:nonNumeric contextRef="i1dbad092e05447cbbaec99507aa54883_D20230501-20230501" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjg0MzYzZjQxZWU2YjQ3MmE5Nzc3YzNiNjZiY2ZhMjZhL3NlYzo4NDM2M2Y0MWVlNmI0NzJhOTc3N2MzYjY2YmNmYTI2YV8xL2ZyYWc6ODVkYmExZWRmOTM0NDBlOTlmNjU5NDhmYTdkOGZkOTMvdGV4dHJlZ2lvbjo4NWRiYTFlZGY5MzQ0MGU5OWY2NTk0OGZhN2Q4ZmQ5M18xNjI4_5561eed9-9e50-4a81-8483-7a4f02f349d5">02210</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:144%">(Address of principal executive offices) (Zip Code)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:144%">(<ix:nonNumeric contextRef="i1dbad092e05447cbbaec99507aa54883_D20230501-20230501" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjg0MzYzZjQxZWU2YjQ3MmE5Nzc3YzNiNjZiY2ZhMjZhL3NlYzo4NDM2M2Y0MWVlNmI0NzJhOTc3N2MzYjY2YmNmYTI2YV8xL2ZyYWc6ODVkYmExZWRmOTM0NDBlOTlmNjU5NDhmYTdkOGZkOTMvdGV4dHJlZ2lvbjo4NWRiYTFlZGY5MzQ0MGU5OWY2NTk0OGZhN2Q4ZmQ5M18xNjIx_dd4f5e86-12b6-4fa5-9a66-7424388195ae">617</ix:nonNumeric>) <ix:nonNumeric contextRef="i1dbad092e05447cbbaec99507aa54883_D20230501-20230501" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjg0MzYzZjQxZWU2YjQ3MmE5Nzc3YzNiNjZiY2ZhMjZhL3NlYzo4NDM2M2Y0MWVlNmI0NzJhOTc3N2MzYjY2YmNmYTI2YV8xL2ZyYWc6ODVkYmExZWRmOTM0NDBlOTlmNjU5NDhmYTdkOGZkOTMvdGV4dHJlZ2lvbjo4NWRiYTFlZGY5MzQ0MGU5OWY2NTk0OGZhN2Q4ZmQ5M18xNjI5_aad944e4-153c-4131-8231-ccff0368880c">341-6100</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">(Registrant's telephone number, including area code)</span></div><div style="padding-left:5.62pt;padding-right:5.62pt;text-align:center"><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):</span></div><div><span><br/></span></div><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:174%"><ix:nonNumeric contextRef="i1dbad092e05447cbbaec99507aa54883_D20230501-20230501" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjg0MzYzZjQxZWU2YjQ3MmE5Nzc3YzNiNjZiY2ZhMjZhL3NlYzo4NDM2M2Y0MWVlNmI0NzJhOTc3N2MzYjY2YmNmYTI2YV8xL2ZyYWc6ODVkYmExZWRmOTM0NDBlOTlmNjU5NDhmYTdkOGZkOTMvdGV4dHJlZ2lvbjo4NWRiYTFlZGY5MzQ0MGU5OWY2NTk0OGZhN2Q4ZmQ5M18xNjMw_b955b7d4-5b0e-4d3a-b00b-759d35885d0f">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:174%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:174%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></div><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:174%"><ix:nonNumeric contextRef="i1dbad092e05447cbbaec99507aa54883_D20230501-20230501" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjg0MzYzZjQxZWU2YjQ3MmE5Nzc3YzNiNjZiY2ZhMjZhL3NlYzo4NDM2M2Y0MWVlNmI0NzJhOTc3N2MzYjY2YmNmYTI2YV8xL2ZyYWc6ODVkYmExZWRmOTM0NDBlOTlmNjU5NDhmYTdkOGZkOTMvdGV4dHJlZ2lvbjo4NWRiYTFlZGY5MzQ0MGU5OWY2NTk0OGZhN2Q4ZmQ5M18xNjI0_e04f45c5-c611-4f63-87c6-01b1ebc0f4a8">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:174%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:174%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </span></div><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:174%"><ix:nonNumeric contextRef="i1dbad092e05447cbbaec99507aa54883_D20230501-20230501" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjg0MzYzZjQxZWU2YjQ3MmE5Nzc3YzNiNjZiY2ZhMjZhL3NlYzo4NDM2M2Y0MWVlNmI0NzJhOTc3N2MzYjY2YmNmYTI2YV8xL2ZyYWc6ODVkYmExZWRmOTM0NDBlOTlmNjU5NDhmYTdkOGZkOTMvdGV4dHJlZ2lvbjo4NWRiYTFlZGY5MzQ0MGU5OWY2NTk0OGZhN2Q4ZmQ5M18xNjIy_90b62d63-d6ca-4979-88fe-72e3818e4202">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:174%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:174%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </span></div><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:174%"><ix:nonNumeric contextRef="i1dbad092e05447cbbaec99507aa54883_D20230501-20230501" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjg0MzYzZjQxZWU2YjQ3MmE5Nzc3YzNiNjZiY2ZhMjZhL3NlYzo4NDM2M2Y0MWVlNmI0NzJhOTc3N2MzYjY2YmNmYTI2YV8xL2ZyYWc6ODVkYmExZWRmOTM0NDBlOTlmNjU5NDhmYTdkOGZkOTMvdGV4dHJlZ2lvbjo4NWRiYTFlZGY5MzQ0MGU5OWY2NTk0OGZhN2Q4ZmQ5M18xNjI1_87dcab12-fcf8-4dda-92fc-a45d3c737230">&#9744;</ix:nonNumeric></span><span style="color:#231f20;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:174%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:174%">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.180%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.847%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.590%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.847%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.036%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:58.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Securities registered pursuant to Section 12(b) of the Act:</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Title of each class</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Trading Symbol</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Name of each exchange on which registered</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i1dbad092e05447cbbaec99507aa54883_D20230501-20230501" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjg0MzYzZjQxZWU2YjQ3MmE5Nzc3YzNiNjZiY2ZhMjZhL3NlYzo4NDM2M2Y0MWVlNmI0NzJhOTc3N2MzYjY2YmNmYTI2YV8xL2ZyYWc6ODVkYmExZWRmOTM0NDBlOTlmNjU5NDhmYTdkOGZkOTMvdGFibGU6YjEwMGYxMzIyMjNjNGIxM2FlNDFiNWZjZjg2ODlhMDkvdGFibGVyYW5nZTpiMTAwZjEzMjIyM2M0YjEzYWU0MWI1ZmNmODY4OWEwOV8yLTAtMS0xLTE1NDUxMA_dd44f1ef-748f-472d-8ff7-94455fd7c527">Common Stock, $0.01 Par Value Per Share</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i1dbad092e05447cbbaec99507aa54883_D20230501-20230501" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjg0MzYzZjQxZWU2YjQ3MmE5Nzc3YzNiNjZiY2ZhMjZhL3NlYzo4NDM2M2Y0MWVlNmI0NzJhOTc3N2MzYjY2YmNmYTI2YV8xL2ZyYWc6ODVkYmExZWRmOTM0NDBlOTlmNjU5NDhmYTdkOGZkOTMvdGFibGU6YjEwMGYxMzIyMjNjNGIxM2FlNDFiNWZjZjg2ODlhMDkvdGFibGVyYW5nZTpiMTAwZjEzMjIyM2M0YjEzYWU0MWI1ZmNmODY4OWEwOV8yLTItMS0xLTE1NDUxMA_f54e6ab4-149b-45c0-9716-58c5adb4edbf">VRTX</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:2pt;padding-left:11.25pt;padding-right:11.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i1dbad092e05447cbbaec99507aa54883_D20230501-20230501" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjg0MzYzZjQxZWU2YjQ3MmE5Nzc3YzNiNjZiY2ZhMjZhL3NlYzo4NDM2M2Y0MWVlNmI0NzJhOTc3N2MzYjY2YmNmYTI2YV8xL2ZyYWc6ODVkYmExZWRmOTM0NDBlOTlmNjU5NDhmYTdkOGZkOTMvdGFibGU6YjEwMGYxMzIyMjNjNGIxM2FlNDFiNWZjZjg2ODlhMDkvdGFibGVyYW5nZTpiMTAwZjEzMjIyM2M0YjEzYWU0MWI1ZmNmODY4OWEwOV8yLTQtMS0xLTE1NDUxMA_219a22bd-9985-400f-aaee-3e45313e4792">The Nasdaq Global Select Market</ix:nonNumeric></span></div></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></div><div><span><br/></span></div><div><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Emerging growth company </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i1dbad092e05447cbbaec99507aa54883_D20230501-20230501" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjg0MzYzZjQxZWU2YjQ3MmE5Nzc3YzNiNjZiY2ZhMjZhL3NlYzo4NDM2M2Y0MWVlNmI0NzJhOTc3N2MzYjY2YmNmYTI2YV8xL2ZyYWc6ODVkYmExZWRmOTM0NDBlOTlmNjU5NDhmYTdkOGZkOTMvdGV4dHJlZ2lvbjo4NWRiYTFlZGY5MzQ0MGU5OWY2NTk0OGZhN2Q4ZmQ5M18xNjIz_9066ae31-51b0-455f-b0f6-05a44cf89397">&#9744;</ix:nonNumeric></span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i84363f41ee6b472a9777c3b66bcfa26a_4"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:144%">Item 2.02.&#160; Results of Operations and Financial Condition.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:144%">&#160;&#160;&#160;&#160;&#160;</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:144%">On May&#160;1, 2023, we issued a press release in which we reported our consolidated financial results for the three months ended March 31, 2023.  A copy of that press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:144%">The information set forth in Exhibit 99.1 shall not be deemed to be &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.</span></div><div id="i84363f41ee6b472a9777c3b66bcfa26a_7"></div><div style="-sec-extract:summary;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:144%">Item 9.01.  Financial Statements and Exhibits.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:144%">&#160;&#160;&#160;&#160;(d)  Exhibits</span></div><div><span><br/></span></div><div style="padding-left:72pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.064%"><tr><td style="width:1.0%"></td><td style="width:8.117%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.075%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Description of Document</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">99.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex-991_q12023.htm">Press Release Dated May 1, 2023.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Cover Page Interactive Data File &#8212; the cover page XBRL tags are embedded within the Inline XBRL document.</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i84363f41ee6b472a9777c3b66bcfa26a_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:144%">SIGNATURES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:144%">&#160; </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:144%">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:144%">&#160;</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.888%"><tr><td style="width:1.0%"></td><td style="width:31.794%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:66.006%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">VERTEX PHARMACEUTICALS INCORPORATED</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:99pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(Registrant)</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Date:  May&#160;1, 2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">/s/ Jonathan Biller</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Jonathan Biller</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Executive Vice President, Chief Legal Officer</span></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex-991_q12023.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i4443300bb25b416d8519529a697d931e_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:174%">Vertex Reports First Quarter 2023 Financial Results</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:174%">&#8212; Product revenue of $2.37 billion, a 13% increase compared to Q1 2022 &#8212;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:174%">&#8212; Company reiterates full year 2023 financial guidance, including product revenue guidance of $9.55 to $9.7 billion &#8212; </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:174%"> &#8212; TRIKAFTA approved in U.S. for children with cystic fibrosis 2 to 5 years of age &#8212;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:174%">&#8212; Pipeline advancement continues with completion of rolling BLA submissions for exa-cel in the U.S.&#59; multiple additional clinical milestones expected in 2023 &#8212; </font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:174%">BOSTON </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">-- Vertex Pharmaceuticals Incorporated (Nasdaq&#58; VRTX) today reported consolidated financial results for the first quarter ended March&#160;31, 2023 and reiterated full year 2023 financial guidance.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">&#8220;Vertex delivered a strong start to 2023, with outstanding execution across our business. We continue to reach more patients globally with our cystic fibrosis medicines and progress our broad and diverse pipeline, most notably completing the rolling BLA submissions for exa-cel in the U.S.,&#8221; said Reshma Kewalramani, M.D., Chief Executive Officer and President of Vertex. &#8220;Over the course of this year, we look forward to continuing to expand our leadership in CF&#59; preparing for near-term launches, including exa-cel&#59; and advancing multiple potentially transformative medicines through mid- and late-stage clinical trials.&#8221;</font></div><div style="margin-bottom:9pt"><font><br></font></div><div id="i4443300bb25b416d8519529a697d931e_7"></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:174%;text-decoration:underline">First Quarter 2023 Results</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:174%">Product revenue </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">increased 13% to $2.37 billion compared to the first quarter of 2022, primarily driven by the strong uptake of TRIKAFTA&#47;KAFTRIO in multiple countries internationally and continued performance of TRIKAFTA in the U.S. Net product revenue in the first quarter of 2023 increased 3% to $1.40 billion in the U.S. and increased 33% to $971 million outside the U.S., compared to the first quarter of 2022.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:174%">Combined GAAP and Non-GAAP R&#38;D, Acquired IPR&#38;D and SG&#38;A expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%"> were $1.3 billion and $1.2 billion, respectively, compared to $818 million and $687 million, respectively, in the first quarter of 2022. The increases were due to higher acquired IPR&#38;D expenses, increased investment in support of multiple programs that have advanced in mid- and late-stage clinical development, and the costs to support launches of Vertex's therapies globally.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:174%">GAAP effective tax rate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%"> was 21.5% compared to 20.2% for the first quarter of 2022.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:174%">Non-GAAP effective tax rate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%"> was 21.3% compared to 21.5% for the first quarter of 2022. Please refer to Note 1 for further details on our GAAP to Non-GAAP tax adjustments.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:174%">GAAP and Non-GAAP net income </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">decreased by 8% and 12%, respectively, compared to the first quarter of 2022, primarily driven by higher acquired IPR&#38;D expenses, increased investment in our mid- and late-stage clinical pipeline, and the costs to support launches of Vertex&#8217;s therapies globally, partially offset by strong revenue growth and increased interest income.</font></div><div id="i4443300bb25b416d8519529a697d931e_386"></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:174%">Cash, cash equivalents and total marketable securities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%"> as of March&#160;31, 2023 were $11.5 billion, compared to $10.9 billion as of December&#160;31, 2022. The increase was primarily driven by strong revenue growth and operating cash flow, partially offset by our upfront payments to Entrada Therapeutics, CRISPR Therapeutics and other collaboration partners, repurchases of our common stock pursuant to our share repurchase program, and income tax payments.</font></div><div style="margin-bottom:9pt"><font><br></font></div><div id="i4443300bb25b416d8519529a697d931e_13"></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:174%;text-decoration:underline">Full Year 2023 Financial Guidance</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">Vertex today reiterated its full year 2023 financial guidance, including CF product revenue guidance of $9.55 to $9.7 billion. Vertex&#8217;s CF product revenue guidance includes expectations in the U.S. for continued performance of TRIKAFTA in ages 6+ and the launch of TRIKAFTA in the 2-5 age group, as well as continued uptake of KAFTRIO&#47;TRIKAFTA in ages 6+ in countries outside the U.S., including those with recent reimbursement agreements. This guidance includes an approximately 150-basis-point negative impact from changes in foreign currency rates, inclusive of our foreign exchange risk management program. </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">Vertex&#8217;s financial guidance is summarized below&#58;</font></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.157%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.346%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current FY 2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Previous FY 2023</font></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">CF product revenues</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unchanged</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$9.55 to $9.7 billion</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Combined GAAP R&#38;D, Acquired IPR&#38;D and SG&#38;A expenses (2)</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unchanged</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$4.35 to $4.6 billion</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Combined Non-GAAP R&#38;D, Acquired IPR&#38;D and SG&#38;A expenses (2)</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unchanged</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$3.9 to $4.0 billion</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-GAAP effective tax rate</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unchanged</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21% to 22%</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</font></div></div></div><div id="i4443300bb25b416d8519529a697d931e_16"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:174%;text-decoration:underline">Key Business Highlights</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:174%;text-decoration:underline">Cystic Fibrosis (CF) Marketed Products </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">Vertex anticipates the number of CF patients taking our medicines will continue to grow, including through new approvals and reimbursement for the treatment of younger patients. Recent progress includes&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;padding-left:13.8pt">Vertex received approval from the U.S. Food and Drug Administration (FDA) for the use of TRIKAFTA in children 2 to 5 years of age with at least one&#8239;F508del&#8239;mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene or a mutation in the&#8239;CFTR&#8239;gene that is responsive to TRIKAFTA. With this approval, approximately 900 children are newly eligible for TRIKAFTA. Vertex has also completed regulatory submissions with the European Medicines Agency (EMA), the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom, Health Canada, and the Therapeutic Goods Administration (TGA) in Australia for the use of KAFTRIO&#47;TRIKAFTA in children 2 to 5 years of age.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;padding-left:13.8pt">Vertex received a positive opinion from the EMA Committee for Medicinal Products for Human Use (CHMP) for the use of ORKAMBI in children 1 to &#60;2 years of age with two copies of the F508del mutation in the CFTR gene. If this label extension is approved by the European Commission, nearly 300 children with CF will be eligible for the first time for a medicine to treat the underlying cause of their disease.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:174%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;padding-left:13.8pt">Vertex has also submitted an sNDA to the FDA and Marketing Authorization Applications (MAAs) to the EMA, MHRA, and Health Canada for the use of KALYDECO in children from 1 month to &#60;4 months of age. The FDA granted Priority Review designation and assigned a PDUFA date of May 3, 2023. </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:174%;text-decoration:underline">Potential Near-Term Launch Opportunities</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">Vertex is preparing for the following near-term potential new product launches&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:174%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:174%;padding-left:13.8pt">Exagamglogene autotemcel (exa-cel), formerly known as CTX001, in severe sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT)&#58; </font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:174%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;padding-left:13.75pt">Vertex completed the rolling submission of its biologics licensing applications (BLAs) in the U.S. The BLAs include requests for Priority Review, which if granted, would shorten the FDA&#8217;s review of the application to eight months from the time of submission versus a standard review timeline of 12 months. In the U.S., exa-cel has been granted Fast Track, </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">Regenerative Medicine Advanced Therapy (RMAT), Orphan Drug and Rare Pediatric Disease designations. </font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;padding-left:13.75pt">In December 2022, Vertex completed regulatory submissions for exa-cel with the EMA and MHRA in the EU and the U.K., respectively. Both the EMA and the MHRA have validated the MAAs, indicating acceptance of the marketing applications and initiation of the review. Exa-cel has been granted Priority Medicines (PRIME) and Orphan Drug designation in the EU. In the U.K., exa-cel has been granted an Innovation Passport under the Innovative Licensing and Access Pathway (ILAP) from the MHRA.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:174%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:174%;padding-left:13.8pt">Vanzacaftor&#47;tezacaftor&#47;deutivacaftor, the next-in-class triple combination, in cystic fibrosis&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">In the fourth quarter of 2022,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:174%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">Vertex completed enrollment in the pivotal SKYLINE 102 and SKYLINE 103 trials, which evaluate the efficacy and safety of vanzacaftor&#47;tezacaftor&#47;deutivacaftor relative to TRIKAFTA in patients with CF 12 years of age and older. Vertex expects to complete the SKYLINE studies by the end of 2023. In parallel, Vertex has initiated a study of vanzacaftor&#47;tezacaftor&#47;deutivacaftor </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">in children with CF 6 to 11 years of age, known as the RIDGELINE study, and the company also expects to complete this study by the end of 2023. </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:174%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:174%;padding-left:13.8pt">VX-548 in acute pain&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%"> Vertex continues to enroll the Phase 3 pivotal program for its lead compound, VX-548, for the treatment of moderate to severe acute pain and expects to complete the pivotal program in late 2023 or early 2024. VX-548 has been granted Breakthrough Therapy and Fast Track designations in the U.S. for moderate to severe acute pain.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:174%;text-decoration:underline">R&#38;D Pipeline</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">Vertex is delivering on a diversified pipeline of potentially transformative small molecule, mRNA, cell and genetic therapies aimed at serious diseases. Recent and anticipated progress for programs in clinical development is summarized below.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:174%">Cystic Fibrosis</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">Vertex continues to pursue next-in-class, small molecule CFTR modulator therapies as well as an mRNA therapy for the approximately 5,000 patients who cannot benefit from CFTR modulators alone.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:174%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;padding-left:13.8pt">Vertex is developing VX-522, a CFTR mRNA therapeutic, in collaboration with Moderna. The goal of this therapy is to treat the underlying cause of CF by programming cells in the lungs to produce functional CFTR protein, and it is aimed at the treatment of the approximately 5,000 people with CF who do not</font><font style="color:#1b252b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">produce any CFTR protein. Vertex has initiated a single ascending </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">dose (SAD) clinical trial for VX-522 in people with CF, which is active and enrolling patients at multiple sites. Vertex expects to complete the SAD and initiate a multiple ascending dose (MAD) study in 2023. In the U.S., the FDA has granted Fast Track designation for VX-522.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:174%">Beta Thalassemia and Sickle Cell Disease</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">Exa-cel is a non-viral </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:174%">ex vivo</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%"> CRISPR gene-editing therapy, which is being developed as a potential functional cure for TDT and SCD. Vertex is developing exa-cel in collaboration with CRISPR Therapeutics.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;padding-left:13.8pt">Dosing in the Phase 1&#47;2&#47;3 CLIMB-111 and CLIMB-121 studies continues, as does the CLIMB-131 long-term follow-up study in patients 12 years of age and older.  </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;padding-left:13.8pt">Two additional Phase 3 studies of exa-cel continue to enroll patients 5 to 11 years of age with TDT or SCD.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:174%">Neuropathic Pain (NaV1.8)</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">Vertex has discovered multiple selective small molecule inhibitors of NaV1.8 with the objective of creating a new class of pain medicines that have the potential to provide effective pain relief, without the limitations of opioids and other currently available medicines.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:174%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;padding-left:13.8pt">Vertex continues to enroll and dose patients in a Phase 2 dose-ranging study of VX-548 in patients with diabetic peripheral neuropathy, a common form of peripheral neuropathic pain.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;padding-left:13.8pt">Vertex expects to complete this study in late 2023 or early 2024.  </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:174%">APOL1-Mediated Kidney Disease (AMKD)</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">Vertex has discovered multiple oral, small molecule inhibitors of APOL1 function, pioneering a new class of medicines that target an underlying genetic driver of kidney disease.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;padding-left:13.8pt">In March, the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:174%">New England Journal of Medicine</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%"> published results from preclinical studies and a Phase 2 study evaluating the efficacy and safety of inaxaplin (VX-147) on top of standard-of-care in people with focal segmental glomerulosclerosis (FSGS) and two APOL1 variants, a form of AMKD. The results from the Phase 2 study of inaxaplin demonstrated a statistically significant and clinically meaningful mean reduction in proteinuria of 47.6% at 13 weeks compared to baseline. Inaxaplin was generally well tolerated in the study. </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;padding-left:13.8pt">Vertex continues to enroll and dose patients in the pivotal program for inaxaplin, a single Phase 2&#47;3 clinical trial in patients with AMKD, and expects to complete the Phase 2B dose-ranging portion of the study in 2023.  </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:174%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;padding-left:13.8pt">Inaxaplin was granted Breakthrough Therapy designation by the FDA for FSGS, as well as Orphan Drug and PRIME designations by the EMA for AMKD. </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:174%">Type 1 Diabetes (T1D)</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">Vertex is evaluating cell therapies using stem-cell derived, fully differentiated, insulin-producing islet cells to replace the endogenous insulin-producing islet cells that are destroyed in people with T1D, with the goal of developing a potential functional cure for this disease. Vertex has three programs that use these fully differentiated cells.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:174%;padding-left:9pt">VX-880, fully differentiated cells with standard immunosuppression&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">Vertex has completed enrollment and dosing in Part B of the Phase 1&#47;2 study of VX-880. Vertex expects to present updated clinical data, including data from more patients and with longer duration of follow-up from the VX-880 study at scientific congresses in 2023, including the American Diabetes Association Scientific Sessions in June. N</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">ext, Vertex intends to begin Part C </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">of the study with concurrent dosing. In March 2023, VX-880 was granted PRIME designation by the EMA.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:174%;padding-left:9pt">VX-264, fully differentiated cells encapsulated in immunoprotective device&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%"> The Investigational New Drug (IND) application in the U.S. and the Clinical Trial Application (CTA) in Canada for VX-264, the cells plus device program, have been cleared, and Vertex plans to begin enrollment and dosing in a Phase 1&#47;2 clinical trial in the near term.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:174%;padding-left:9pt">Edited fully differentiated cells&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">Vertex&#8217;s hypoimmune cell research program continues to progress. </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">In addition, a Phase 1&#47;2 study of VCTX-211, a hypoimmune cell program using ViaCyte cells that originated under the CRISPR Therapeutics and ViaCyte collaboration, is active and enrolling patients.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:174%">Alpha-1 Antitrypsin Deficiency</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">Vertex is working to address the underlying genetic cause of alpha-1 antitrypsin (AAT) deficiency by developing novel small molecule correctors of Z-AAT protein folding, with a goal of increasing the secretion of functional AAT into the blood and addressing both the lung and the liver aspects of AAT deficiency.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:174%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;padding-left:13.8pt">Vertex initiated a 48-week Phase 2 study of VX-864, a first-generation AAT corrector, to assess the impact of longer-term treatment on polymer clearance from the liver, as well as the resultant levels of functional AAT (fAAT) in the plasma. This Phase 2 trial continues to enroll and dose patients.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:174%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;padding-left:13.8pt">Additionally, Vertex continues to enroll and dose healthy volunteers with VX-634, a follow-on small molecule AAT corrector. VX-634 is the first in a series of next-wave investigational molecules with significantly improved potency and drug-like properties compared to previous Vertex AAT correctors.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:174%">Additional Earlier Stage R&#38;D Programs</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">Consistent with its overall strategy, Vertex takes a portfolio approach to all of its programs, with additional assets in CF, SCD, TDT, pain, AMKD, T1D and AATD in earlier stages of development. </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">Vertex is also advancing preclinical assets in new disease areas, such as Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1). Additionally, Vertex is working on preclinical molecules with the potential to expand our leadership in existing disease areas, including assets targeting gentler conditioning for exa-cel and NaV1.7 in pain. </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:174%">Investments in External Innovation</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">Consistent with its strategy to develop transformative medicines for serious diseases, in the first quarter of 2023, Vertex announced a new licensing agreement for the use of CRISPR Therapeutics&#8217; gene editing technology, known as CRISPR&#47;Cas9, to accelerate the development of Vertex&#8217;s hypoimmune cell therapies for T1D. Under this agreement, Vertex made an upfront payment of $100 million to CRISPR in the first quarter of 2023. </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">In addition, the previously announced global research collaboration with Entrada Therapeutics, focused on therapeutics for DM1, has closed. Under the terms of the agreement, upon closing, Vertex made an upfront payment of approximately $225 million to Entrada, as well as an equity investment of approximately $25 million. </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</font></div></div></div><div id="i4443300bb25b416d8519529a697d931e_19"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Non-GAAP Financial Measures</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In this press release, Vertex's financial results and financial guidance are provided in accordance with accounting principles generally accepted in the United States (GAAP) and using certain non-GAAP financial measures. In particular, non-GAAP financial results and guidance exclude from Vertex's pre-tax income (i) stock-based compensation expense, (ii) gains or losses related to the fair value of the company's strategic investments, (iii) increases or decreases in the fair value of contingent consideration, (iv) acquisition-related costs, and (v) other adjustments. The company's non-GAAP financial results also exclude from its provision for income taxes the estimated tax impact related to its non-GAAP adjustments to pre-tax income described above and certain discrete items. These results should not be viewed as a substitute for the company&#8217;s GAAP results and are provided as a complement to results provided in accordance with GAAP. Management believes these non-GAAP financial measures help indicate underlying trends in the company's business, are important in comparing current results with prior period results and provide additional information regarding the company's financial position that the company believes is helpful to an understanding of its ongoing business. Management also uses these non-GAAP financial measures to establish budgets and operational goals that are communicated internally and externally, to manage the company's business and to evaluate its performance. The company&#8217;s calculation of non-GAAP financial measures likely differs from the calculations used by other companies. A reconciliation of the GAAP financial results to non-GAAP financial results is included in the attached financial information.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The company provides guidance regarding combined R&#38;D, Acquired IPR&#38;D and SG&#38;A expenses and effective tax rate on a non-GAAP basis. Unless otherwise noted, the guidance regarding combined GAAP and non-GAAP R&#38;D, Acquired IPR&#38;D and SG&#38;A expenses does not include estimates associated with any potential future business development transactions, including collaborations, asset acquisitions and&#47;or licensing of third-party intellectual property rights. The company does not provide guidance regarding its GAAP effective tax rate because it is unable to forecast with reasonable certainty the impact of excess tax benefits related to stock-based compensation and the possibility of certain discrete items, which could be material. </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</font></div></div></div><div id="i4443300bb25b416d8519529a697d931e_22"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Vertex Pharmaceuticals Incorporated</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Consolidated Statements of Income</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(in millions, except per share amounts)(unaudited)</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.935%"><tr><td style="width:1.0%"></td><td style="width:63.208%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:16.102%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.086%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.104%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenues, net</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,374.8&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,097.5&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs and expenses&#58;</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">266.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">742.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">601.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired in-process research and development expenses</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.9)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.5)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total costs and expenses</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,595.8&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,056.6&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from operations</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">779.0&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,040.9&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.4)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.9)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(72.8)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income before provision for income taxes</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">891.5&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">954.8&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">699.8&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">762.1&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per common share&#58;</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.72&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.99&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.69&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.96&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares used in per share calculations&#58;</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">260.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div id="i4443300bb25b416d8519529a697d931e_332"></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Vertex Pharmaceuticals Incorporated</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Product Revenues</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(in millions)(unaudited)</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.935%"><tr><td style="width:1.0%"></td><td style="width:63.208%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:16.102%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.086%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.104%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TRIKAFTA&#47;KAFTRIO</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,096.7&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,761.6&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other CF products</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">278.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">335.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenues, net</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,374.8&#160;</font></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,097.5&#160;</font></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</font></div></div></div><div id="i4443300bb25b416d8519529a697d931e_357"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Vertex Pharmaceuticals Incorporated</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Reconciliation of GAAP to Non-GAAP Financial Information</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(in millions, except percentages)(unaudited)</font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.935%"><tr><td style="width:1.0%"></td><td style="width:63.208%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:16.102%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.086%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.104%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">GAAP cost of sales</font></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">266.9&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245.8&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.9)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.2)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:33.75pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-GAAP cost of sales</font></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">265.0&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">243.6&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">GAAP research and development expenses</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">742.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">601.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(76.3)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(80.4)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition-related costs (3)</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.8)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.8)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 34.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-GAAP research and development expenses</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">663.5&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">517.9&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Acquired in-process research and development expenses</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">GAAP selling, general and administrative expenses</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44.2)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47.7)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 34.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-GAAP selling, general and administrative expenses</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196.9&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167.5&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 34.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Combined non-GAAP R&#38;D, Acquired IPR&#38;D and SG&#38;A expenses</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,207.5&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">687.4&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">GAAP other income (expense), net</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(72.8)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Increase) decrease in fair value of strategic investments</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.4)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 34.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-GAAP other (expense) income, net</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.1)</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">GAAP provision for income taxes</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax adjustments (1)</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 34.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-GAAP provision for income taxes</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214.4&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248.9&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.081%"><tr><td style="width:1.0%"></td><td style="width:63.265%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:16.074%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.084%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.077%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">GAAP effective tax rate</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-GAAP effective tax rate</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</font></div></div></div><div id="i4443300bb25b416d8519529a697d931e_25"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Vertex Pharmaceuticals Incorporated</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Reconciliation of GAAP to Non-GAAP Financial Information (continued)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(in millions, except per share amounts)(unaudited)</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.935%"><tr><td style="width:1.0%"></td><td style="width:63.208%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:16.102%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.086%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.104%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt 0 12.25pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</font></td></tr><tr><td colspan="3" style="padding:0 1pt 0 12.25pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">GAAP operating income</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">779.0&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,040.9&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decrease in fair value of contingent consideration</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.9)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.5)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition-related costs (3)</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 34.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-GAAP operating income</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">902.3&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,166.5&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">GAAP net income</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">699.8&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">762.1&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Increase) decrease in fair value of strategic investments</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.4)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decrease in fair value of contingent consideration</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.9)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.5)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition-related costs (3)</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 34pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total non-GAAP adjustments to pre-tax income</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116.9&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201.2&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax adjustments (1)</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22.7)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(56.2)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 34.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-GAAP net income</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">794.0&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">907.1&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per diluted common share&#58;</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GAAP</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.69&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.96&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-GAAP</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.05&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.52&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares used in diluted per share calculations&#58;</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GAAP and Non-GAAP</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">260.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</font></div></div></div><div id="i4443300bb25b416d8519529a697d931e_28"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Vertex Pharmaceuticals Incorporated</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Condensed Consolidated Balance Sheets</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(in millions)(unaudited)</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.713%"><tr><td style="width:1.0%"></td><td style="width:56.154%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.048%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.650%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and marketable securities</font></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,414.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,778.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,547.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,442.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">535.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">460.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">468.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">553.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total current assets</font></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,965.7&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,234.8&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,111.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,108.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill and intangible assets</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,691.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,691.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,359.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,246.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease assets</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">336.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term marketable securities</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,081.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">427.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">409.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total assets</font></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,974.2&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,150.9&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities and Shareholders' Equity</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued expenses</font></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,649.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,430.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">377.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">311.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total current liabilities</font></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,026.2&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,742.1&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term finance lease liabilities</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">417.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">430.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term operating lease liabilities</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">371.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">379.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">726.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">685.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shareholders' equity</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,432.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,912.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;Total liabilities and shareholders' equity</font></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,974.2&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,150.9&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common shares outstanding</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</font></div></div></div><div id="i4443300bb25b416d8519529a697d931e_31"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Notes and Explanations</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> In the three months ended March 31, 2023 and 2022, &#34;Tax adjustments&#34; included the estimated income taxes related to non-GAAP adjustments to the company's pre-tax income and excess tax benefits related to stock-based compensation.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">2&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The difference between the company&#8217;s full year 2023 combined GAAP R&#38;D, Acquired IPR&#38;D and SG&#38;A expenses and combined non-GAAP R&#38;D, Acquired IPR&#38;D and SG&#38;A expenses guidance relates primarily to $440 million to $575 million of stock-based compensation expense. Unless otherwise noted, the guidance regarding combined GAAP and non-GAAP R&#38;D, Acquired IPR&#38;D and SG&#38;A expenses does not include estimates associated with any potential future business development transactions, including collaborations, asset acquisitions and&#47;or licensing of third-party intellectual property rights.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">3&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#34;Acquisition-related costs&#34; in the three months ended March 31, 2023 and 2022 related to costs associated with the company's acquisition of Exonics.</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Note</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%"> Amounts may not foot due to rounding.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</font></div></div></div><div id="i4443300bb25b416d8519529a697d931e_34"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">About Vertex</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has multiple approved medicines that treat the underlying cause of cystic fibrosis (CF) &#8212; a rare, life-threatening genetic disease &#8212; and has several ongoing clinical and research programs in CF. Beyond CF, Vertex has a robust clinical pipeline of investigational small molecule, mRNA, cell and genetic therapies (including gene editing) in other serious diseases where it has deep insight into causal human biology, including sickle cell disease, beta thalassemia, APOL1-mediated kidney disease, acute and neuropathic pain, type 1 diabetes and alpha-1 antitrypsin deficiency.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Founded in 1989 in Cambridge, Mass., Vertex's global headquarters is now located in Boston's Innovation District and its international headquarters is in London. Additionally, the company has research and development sites and commercial offices in North America, Europe, Australia and Latin America. Vertex is consistently recognized as one of the industry's top places to work, including 13 consecutive years on Science magazine's Top Employers list and one of Fortune&#8217;s 100 Best Companies to Work For. For company updates and to learn more about Vertex's history of innovation, visit www.vrtx.com or follow us on Facebook, Twitter, LinkedIn, YouTube and Instagram.</font></div><div><font><br></font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Special Note Regarding Forward-Looking Statements</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, Dr. Kewalramani's statements in this press release, the information provided regarding future financial performance and operations, the section captioned &#34;Full Year 2023 Financial Guidance&#34; and statements regarding (i) expectations for continued growth in the number of people eligible and treated with our CF medicines, including expectations that nearly 300 children with CF will be eligible for a medicine for the first time if&#47;when ORKAMBI is approved for children 1 to &#60;2 years of age in Europe, and expansion of treatment options for the patients who cannot benefit from CFTR modulators alone, (ii) the expectations, development plans and anticipated timelines for the company's products and product candidates and pipeline programs, study designs, patient enrollment, data availability, potential launches and timing thereof, (iii) the expectations, plans, and status of potential near-term product commercial launches, including those for exa-cel in SCD and TDT, vanzacaftor&#47;tezacaftor&#47;deutivacaftor in CF, and VX-548 in moderate to severe acute pain, (iv) recent and anticipated regulatory filings, and data availability, as well as expectations regarding timing and regulatory review thereof, (v) expectations regarding our collaboration with Moderna to develop CFTR mRNA therapeutics, and plans to complete the single-ascending dose study and initiate the multiple-ascending dose study for VX-522 in 2023, (vi) expectations regarding the potential benefits of exa-cel as a functional cure for TDT and SCD, (vii) expectations regarding the potential benefits and objectives of our pain program and products, including the expectation to complete the Phase 2 dose-ranging study of VX-548 in peripheral neuropathic pain in late 2023 or early 2024, (viii) expectations regarding the potential benefits of our AMKD program, and plans regarding our Phase 2&#47;3 study of inaxaplin, including expectations to complete the Phase 2B dose-ranging portion of the study in 2023, (ix) expectations regarding the potential benefits of our T1D program, including our plans to continue to progress the Phase 1&#47;2 program of VX-880, including expectations to present updated clinical data from the study at a scientific congress in 2023 and to begin Part C of the study, as well as our plans regarding our additional programs in T1D, including plans to begin enrollment and dosing in a Phase 1&#47;2 clinical trial for VX-264 in the near term, (x) our expectations regarding our goals and the potential benefits of our AAT deficiency program and plans to continue to advance VX-864 and VX-634 in clinical trials, (xi) plans with respect to our additional earlier stage research and development programs, including preclinical assets in new </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">disease areas such as DMD and DM1, and assets targeting gentler conditioning for exa-cel and NaV1.7 in pain, and (xii) expectations with respect to our investments in external innovation, including our belief that the CRISPR&#47;Cas9 technology will accelerate development of our hypoimmune cell therapies for T1D. While Vertex believes the forward-looking statements contained in this press release are accurate, these forward-looking statements represent the company's beliefs only as of the date of this press release and there are a number of risks and uncertainties that could cause actual events or results to differ materially from those expressed or implied by such forward-looking statements. Those risks and uncertainties include, among other things, that the company's expectations regarding its 2023 product revenues, expenses and effective tax rates may be incorrect (including because one or more of the company's assumptions underlying its expectations may not be realized), that the company may not be able to receive regulatory approval for exa-cel on the expected timeline, or at all, that external factors may have different or more significant impacts on the company's business or operations than the company currently expects, that data from preclinical testing or clinical trials, especially if based on a limited number of patients, may not be indicative of final results or available on anticipated timelines, that patient enrollment in our trials may be delayed, that the company may not realize the anticipated benefits from our collaborations with third parties, that data from the company's development programs may not support registration or further development of its potential medicines in a timely manner, or at all, due to safety, efficacy or other reasons, that anticipated commercial launches may be delayed, if they occur at all, and other risks listed under the heading &#8220;Risk Factors&#8221; in Vertex's annual report and subsequent quarterly reports filed with the Securities and Exchange Commission (SEC) and available through the company's website at www.vrtx.com and on the SEC&#8217;s website at www.sec.gov. You should not place undue reliance on these statements, or the scientific data presented. Vertex disclaims any obligation to update the information contained in this press release as new information becomes available.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Conference Call and Webcast</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The company will host a conference call and webcast at 4&#58;30 p.m. ET. To access the call, please dial (877) 270-2148 (U.S.) or +1 (412) 902-6510 (International) and reference the &#8220;Vertex Pharmaceuticals First Quarter 2023 Earnings Call.&#8221;</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The conference call will be webcast live and a link to the webcast can be accessed through Vertex's website at www.vrtx.com in the &#34;Investors&#34; section. To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast. An archived webcast will be available on the company's website.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">(VRTX-E) </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Vertex Contacts&#58; </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Investor Relations&#58; </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Susie Lisa, CFA, 617-341-6108</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Manisha Pai, 617-961-1899</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Miroslava Minkova, 617-341-6135</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Media&#58; </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">617-341-6992 </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">mediainfo&#64;vrtx.com </font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>vrtx-20230501.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:39b77e58-d50b-4e87-a966-5773b7766a3f,g:48973149-c2d4-4722-94fe-ccce81753841-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:vrtx="http://www.vrtx.com/20230501" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.vrtx.com/20230501">
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="vrtx-20230501_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="vrtx-20230501_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="DocumentandEntityInformationDocument" roleURI="http://www.vrtx.com/role/DocumentandEntityInformationDocument">
        <link:definition>0000001 - Document - Document and Entity Information Document</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>vrtx-20230501_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:39b77e58-d50b-4e87-a966-5773b7766a3f,g:48973149-c2d4-4722-94fe-ccce81753841-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_EntityTaxIdentificationNumber_28382e56-1619-49ca-b86e-75ec85a54817_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_9507e3ec-17ed-4e1b-8316-5b692efea2ed_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_ae9eb42b-7a5d-4cb5-8e61-0949db59558a_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_5e0f9106-9d8b-4678-92a3-8693b5c4961f_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_7abac9b3-b2f6-4a4a-9328-c29853ea0423_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_cf3a2192-3d52-49c8-8611-ec17622bc715_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_03bd241b-d98d-4f59-a6d1-e5e1288f344f_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_2d40f26d-2710-4fd6-8879-11fab3eb2dab_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_a36dd6e4-1477-41ac-b0f0-b364ac832a34_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_ec699129-efaa-4a02-80d6-5bc73d2eec82_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_32101079-1330-4849-a30f-29690d712a87_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_8cd7849b-cb38-4cb8-9c4b-2e81b8dc567d_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_d3d67afb-0ede-44fb-bacb-1652f65f425d_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_ebd91503-483b-4145-9d7d-9f00e3e64812_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_65cff59c-e18c-446c-b23e-52fd170b7f28_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_50731090-17ff-4080-b355-3de666a1ec27_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_d27b5b95-7747-416b-903a-9dcf6fc48a9f_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_2391c515-2897-4565-a68c-97b4ee9882d5_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_8d672b7a-f83b-4b72-87f4-66a6f8770bd5_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_73bbd6bc-64f5-40f4-9cb1-fb8bd7d160d5_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_48d324ec-9c75-4620-a546-6a72a75bb827_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_98cde67f-7d72-425e-8c96-b968ebcb818d_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_ffd0ef34-5ab0-42ea-bd32-7ffb0bcb5024_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>vrtx-20230501_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:39b77e58-d50b-4e87-a966-5773b7766a3f,g:48973149-c2d4-4722-94fe-ccce81753841-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.vrtx.com/role/DocumentandEntityInformationDocument" xlink:type="simple" xlink:href="vrtx-20230501.xsd#DocumentandEntityInformationDocument"/>
  <link:presentationLink xlink:role="http://www.vrtx.com/role/DocumentandEntityInformationDocument" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_364217af-ff21-44e9-8610-0b68f566fdb8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_7ae4f590-4381-4168-a500-1b721490276f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_364217af-ff21-44e9-8610-0b68f566fdb8" xlink:to="loc_dei_DocumentType_7ae4f590-4381-4168-a500-1b721490276f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_dad9e84c-30bf-4cf7-b6ae-543d31fb98a0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_364217af-ff21-44e9-8610-0b68f566fdb8" xlink:to="loc_dei_DocumentPeriodEndDate_dad9e84c-30bf-4cf7-b6ae-543d31fb98a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_db886fcd-1493-4ea5-8a79-fb7b40485827" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_364217af-ff21-44e9-8610-0b68f566fdb8" xlink:to="loc_dei_EntityRegistrantName_db886fcd-1493-4ea5-8a79-fb7b40485827" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_2fa0e4bc-e2f9-47c0-9858-ee5061ed8405" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_364217af-ff21-44e9-8610-0b68f566fdb8" xlink:to="loc_dei_EntityCentralIndexKey_2fa0e4bc-e2f9-47c0-9858-ee5061ed8405" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_07f8d446-153a-46e9-9cf9-506ca38825c1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_364217af-ff21-44e9-8610-0b68f566fdb8" xlink:to="loc_dei_AmendmentFlag_07f8d446-153a-46e9-9cf9-506ca38825c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_05fae98d-3ad0-4c2e-a848-8be2afd7c7f8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_364217af-ff21-44e9-8610-0b68f566fdb8" xlink:to="loc_dei_EntityIncorporationStateCountryCode_05fae98d-3ad0-4c2e-a848-8be2afd7c7f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_de23a750-4db3-4a86-9840-545b6369747c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_364217af-ff21-44e9-8610-0b68f566fdb8" xlink:to="loc_dei_EntityFileNumber_de23a750-4db3-4a86-9840-545b6369747c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_da617540-7cbf-43ec-a445-9059f0ef2d8c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_364217af-ff21-44e9-8610-0b68f566fdb8" xlink:to="loc_dei_EntityTaxIdentificationNumber_da617540-7cbf-43ec-a445-9059f0ef2d8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_427d7d9e-035f-4e0a-a3d9-791b3a072c04" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_364217af-ff21-44e9-8610-0b68f566fdb8" xlink:to="loc_dei_EntityAddressAddressLine1_427d7d9e-035f-4e0a-a3d9-791b3a072c04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_b320f670-9d5d-45d7-b2a5-8130ce7a7265" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_364217af-ff21-44e9-8610-0b68f566fdb8" xlink:to="loc_dei_EntityAddressCityOrTown_b320f670-9d5d-45d7-b2a5-8130ce7a7265" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_be7d0e28-46c4-4d7c-8fee-6a2fdeaf5654" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_364217af-ff21-44e9-8610-0b68f566fdb8" xlink:to="loc_dei_EntityAddressStateOrProvince_be7d0e28-46c4-4d7c-8fee-6a2fdeaf5654" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_874d7b84-3ac9-4c0d-b94e-e1bf1a324f85" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_364217af-ff21-44e9-8610-0b68f566fdb8" xlink:to="loc_dei_EntityAddressPostalZipCode_874d7b84-3ac9-4c0d-b94e-e1bf1a324f85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_5169763e-62f8-44da-8b67-f8122c39f354" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_364217af-ff21-44e9-8610-0b68f566fdb8" xlink:to="loc_dei_CityAreaCode_5169763e-62f8-44da-8b67-f8122c39f354" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_ceaf58ed-252b-40a5-9fef-c7c7f5f50fe5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_364217af-ff21-44e9-8610-0b68f566fdb8" xlink:to="loc_dei_LocalPhoneNumber_ceaf58ed-252b-40a5-9fef-c7c7f5f50fe5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_a3d47904-e8b9-4db0-85f4-59b237e2f836" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_364217af-ff21-44e9-8610-0b68f566fdb8" xlink:to="loc_dei_WrittenCommunications_a3d47904-e8b9-4db0-85f4-59b237e2f836" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_e13834bf-f85d-4ebe-8927-52c09474d67a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_364217af-ff21-44e9-8610-0b68f566fdb8" xlink:to="loc_dei_SolicitingMaterial_e13834bf-f85d-4ebe-8927-52c09474d67a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_d43df669-8988-4350-bc39-4f14c15da4cb" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_364217af-ff21-44e9-8610-0b68f566fdb8" xlink:to="loc_dei_PreCommencementTenderOffer_d43df669-8988-4350-bc39-4f14c15da4cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_6f4501c3-1b26-40d8-8367-406051dc4f5e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_364217af-ff21-44e9-8610-0b68f566fdb8" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_6f4501c3-1b26-40d8-8367-406051dc4f5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_b9e0d462-4edd-4a47-9104-27932c53f7ca" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_364217af-ff21-44e9-8610-0b68f566fdb8" xlink:to="loc_dei_Security12bTitle_b9e0d462-4edd-4a47-9104-27932c53f7ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_066adbba-171a-48bc-9daa-1b671163f0bb" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_364217af-ff21-44e9-8610-0b68f566fdb8" xlink:to="loc_dei_TradingSymbol_066adbba-171a-48bc-9daa-1b671163f0bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_456a9426-e79e-4c44-80c4-f5043d49d094" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_364217af-ff21-44e9-8610-0b68f566fdb8" xlink:to="loc_dei_SecurityExchangeName_456a9426-e79e-4c44-80c4-f5043d49d094" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_6c025ef7-af27-43d0-96cf-50837cf816e1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_364217af-ff21-44e9-8610-0b68f566fdb8" xlink:to="loc_dei_EntityEmergingGrowthCompany_6c025ef7-af27-43d0-96cf-50837cf816e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>6
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139629624607680">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information Document<br></strong></div></th>
<th class="th"><div>May 01, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">May  01,  2023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">VERTEX PHARMACEUTICALS INC / MA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000875320<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">MA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-19319<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">04-3039129<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">50 Northern Avenue<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Boston<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02210<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">617<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">341-6100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.01 Par Value Per Share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">VRTX<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>vrtx-20230501_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="vrtx-20230501.xsd" xlink:type="simple"/>
    <context id="i1dbad092e05447cbbaec99507aa54883_D20230501-20230501">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875320</identifier>
        </entity>
        <period>
            <startDate>2023-05-01</startDate>
            <endDate>2023-05-01</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="i1dbad092e05447cbbaec99507aa54883_D20230501-20230501"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0MzYzZjQxZWU2YjQ3MmE5Nzc3YzNiNjZiY2ZhMjZhL3NlYzo4NDM2M2Y0MWVlNmI0NzJhOTc3N2MzYjY2YmNmYTI2YV8xMy9mcmFnOjUyMjhmMTQyYWIxYTRiNTdiODhhMjE3YmIzYWM5YmMxL3RhYmxlOjM4MTFkMTE1NjlmYjQ2Y2JhMjg5NzA4YmU3OTFiZjI3L3RhYmxlcmFuZ2U6MzgxMWQxMTU2OWZiNDZjYmEyODk3MDhiZTc5MWJmMjdfMi0xLTEtMS0xNTQ1MTA_c5b55de1-b824-4256-9b44-92857cabf57f">0000875320</dei:EntityCentralIndexKey>
    <dei:EntityRegistrantName
      contextRef="i1dbad092e05447cbbaec99507aa54883_D20230501-20230501"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0MzYzZjQxZWU2YjQ3MmE5Nzc3YzNiNjZiY2ZhMjZhL3NlYzo4NDM2M2Y0MWVlNmI0NzJhOTc3N2MzYjY2YmNmYTI2YV8xMy9mcmFnOjUyMjhmMTQyYWIxYTRiNTdiODhhMjE3YmIzYWM5YmMxL3RhYmxlOjM4MTFkMTE1NjlmYjQ2Y2JhMjg5NzA4YmU3OTFiZjI3L3RhYmxlcmFuZ2U6MzgxMWQxMTU2OWZiNDZjYmEyODk3MDhiZTc5MWJmMjdfMy0xLTEtMS0xNTQ1MTA_f54643c8-a5b1-44f6-8811-3a57783383cd">VERTEX PHARMACEUTICALS INC / MA</dei:EntityRegistrantName>
    <dei:AmendmentFlag
      contextRef="i1dbad092e05447cbbaec99507aa54883_D20230501-20230501"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0MzYzZjQxZWU2YjQ3MmE5Nzc3YzNiNjZiY2ZhMjZhL3NlYzo4NDM2M2Y0MWVlNmI0NzJhOTc3N2MzYjY2YmNmYTI2YV8xMy9mcmFnOjUyMjhmMTQyYWIxYTRiNTdiODhhMjE3YmIzYWM5YmMxL3RhYmxlOjM4MTFkMTE1NjlmYjQ2Y2JhMjg5NzA4YmU3OTFiZjI3L3RhYmxlcmFuZ2U6MzgxMWQxMTU2OWZiNDZjYmEyODk3MDhiZTc5MWJmMjdfNi0xLTEtMS0xNTQ1MTA_5c916cd9-b16a-4eda-9f74-e76658da6afb">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="i1dbad092e05447cbbaec99507aa54883_D20230501-20230501"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0MzYzZjQxZWU2YjQ3MmE5Nzc3YzNiNjZiY2ZhMjZhL3NlYzo4NDM2M2Y0MWVlNmI0NzJhOTc3N2MzYjY2YmNmYTI2YV8xL2ZyYWc6ODVkYmExZWRmOTM0NDBlOTlmNjU5NDhmYTdkOGZkOTMvdGV4dHJlZ2lvbjo4NWRiYTFlZGY5MzQ0MGU5OWY2NTk0OGZhN2Q4ZmQ5M18xNjE5_5448ecc1-ebb0-4c94-9360-49f74a92a785">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="i1dbad092e05447cbbaec99507aa54883_D20230501-20230501"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0MzYzZjQxZWU2YjQ3MmE5Nzc3YzNiNjZiY2ZhMjZhL3NlYzo4NDM2M2Y0MWVlNmI0NzJhOTc3N2MzYjY2YmNmYTI2YV8xL2ZyYWc6ODVkYmExZWRmOTM0NDBlOTlmNjU5NDhmYTdkOGZkOTMvdGV4dHJlZ2lvbjo4NWRiYTFlZGY5MzQ0MGU5OWY2NTk0OGZhN2Q4ZmQ5M18yMjU_3f5b0cb7-f870-4852-bd87-a372cb953bcf">2023-05-01</dei:DocumentPeriodEndDate>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i1dbad092e05447cbbaec99507aa54883_D20230501-20230501"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0MzYzZjQxZWU2YjQ3MmE5Nzc3YzNiNjZiY2ZhMjZhL3NlYzo4NDM2M2Y0MWVlNmI0NzJhOTc3N2MzYjY2YmNmYTI2YV8xL2ZyYWc6ODVkYmExZWRmOTM0NDBlOTlmNjU5NDhmYTdkOGZkOTMvdGFibGU6OTJkN2UwMmExMWM0NGY4MThhNWEyMDE4MzgzOTViN2QvdGFibGVyYW5nZTo5MmQ3ZTAyYTExYzQ0ZjgxOGE1YTIwMTgzODM5NWI3ZF8wLTAtMS0xLTE1NDUxMA_cc3626ee-16e2-4885-843d-8c23d1f1b08d">MA</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="i1dbad092e05447cbbaec99507aa54883_D20230501-20230501"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0MzYzZjQxZWU2YjQ3MmE5Nzc3YzNiNjZiY2ZhMjZhL3NlYzo4NDM2M2Y0MWVlNmI0NzJhOTc3N2MzYjY2YmNmYTI2YV8xL2ZyYWc6ODVkYmExZWRmOTM0NDBlOTlmNjU5NDhmYTdkOGZkOTMvdGFibGU6OTJkN2UwMmExMWM0NGY4MThhNWEyMDE4MzgzOTViN2QvdGFibGVyYW5nZTo5MmQ3ZTAyYTExYzQ0ZjgxOGE1YTIwMTgzODM5NWI3ZF8wLTEtMS0xLTE1NDUxMA_70125e48-db21-48bd-a116-b6ae383615ad">000-19319</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="i1dbad092e05447cbbaec99507aa54883_D20230501-20230501"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0MzYzZjQxZWU2YjQ3MmE5Nzc3YzNiNjZiY2ZhMjZhL3NlYzo4NDM2M2Y0MWVlNmI0NzJhOTc3N2MzYjY2YmNmYTI2YV8xL2ZyYWc6ODVkYmExZWRmOTM0NDBlOTlmNjU5NDhmYTdkOGZkOTMvdGFibGU6OTJkN2UwMmExMWM0NGY4MThhNWEyMDE4MzgzOTViN2QvdGFibGVyYW5nZTo5MmQ3ZTAyYTExYzQ0ZjgxOGE1YTIwMTgzODM5NWI3ZF8wLTItMS0xLTE1NDUxMA_0aa8d63e-b598-4dbc-a8e0-fc379975dfc7">04-3039129</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i1dbad092e05447cbbaec99507aa54883_D20230501-20230501"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0MzYzZjQxZWU2YjQ3MmE5Nzc3YzNiNjZiY2ZhMjZhL3NlYzo4NDM2M2Y0MWVlNmI0NzJhOTc3N2MzYjY2YmNmYTI2YV8xL2ZyYWc6ODVkYmExZWRmOTM0NDBlOTlmNjU5NDhmYTdkOGZkOTMvdGV4dHJlZ2lvbjo4NWRiYTFlZGY5MzQ0MGU5OWY2NTk0OGZhN2Q4ZmQ5M18xNjI2_6d41c32a-cc43-4dca-8ccc-23926ee1e094">50 Northern Avenue</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i1dbad092e05447cbbaec99507aa54883_D20230501-20230501"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0MzYzZjQxZWU2YjQ3MmE5Nzc3YzNiNjZiY2ZhMjZhL3NlYzo4NDM2M2Y0MWVlNmI0NzJhOTc3N2MzYjY2YmNmYTI2YV8xL2ZyYWc6ODVkYmExZWRmOTM0NDBlOTlmNjU5NDhmYTdkOGZkOTMvdGV4dHJlZ2lvbjo4NWRiYTFlZGY5MzQ0MGU5OWY2NTk0OGZhN2Q4ZmQ5M18xNjIw_d3eda62c-25af-4d29-9eae-788da80b847f">Boston</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i1dbad092e05447cbbaec99507aa54883_D20230501-20230501"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0MzYzZjQxZWU2YjQ3MmE5Nzc3YzNiNjZiY2ZhMjZhL3NlYzo4NDM2M2Y0MWVlNmI0NzJhOTc3N2MzYjY2YmNmYTI2YV8xL2ZyYWc6ODVkYmExZWRmOTM0NDBlOTlmNjU5NDhmYTdkOGZkOTMvdGV4dHJlZ2lvbjo4NWRiYTFlZGY5MzQ0MGU5OWY2NTk0OGZhN2Q4ZmQ5M18xNjI3_ec8c6ad3-15fc-4460-b9dc-33ce030f1349">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i1dbad092e05447cbbaec99507aa54883_D20230501-20230501"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0MzYzZjQxZWU2YjQ3MmE5Nzc3YzNiNjZiY2ZhMjZhL3NlYzo4NDM2M2Y0MWVlNmI0NzJhOTc3N2MzYjY2YmNmYTI2YV8xL2ZyYWc6ODVkYmExZWRmOTM0NDBlOTlmNjU5NDhmYTdkOGZkOTMvdGV4dHJlZ2lvbjo4NWRiYTFlZGY5MzQ0MGU5OWY2NTk0OGZhN2Q4ZmQ5M18xNjI4_5561eed9-9e50-4a81-8483-7a4f02f349d5">02210</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i1dbad092e05447cbbaec99507aa54883_D20230501-20230501"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0MzYzZjQxZWU2YjQ3MmE5Nzc3YzNiNjZiY2ZhMjZhL3NlYzo4NDM2M2Y0MWVlNmI0NzJhOTc3N2MzYjY2YmNmYTI2YV8xL2ZyYWc6ODVkYmExZWRmOTM0NDBlOTlmNjU5NDhmYTdkOGZkOTMvdGV4dHJlZ2lvbjo4NWRiYTFlZGY5MzQ0MGU5OWY2NTk0OGZhN2Q4ZmQ5M18xNjIx_dd4f5e86-12b6-4fa5-9a66-7424388195ae">617</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i1dbad092e05447cbbaec99507aa54883_D20230501-20230501"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0MzYzZjQxZWU2YjQ3MmE5Nzc3YzNiNjZiY2ZhMjZhL3NlYzo4NDM2M2Y0MWVlNmI0NzJhOTc3N2MzYjY2YmNmYTI2YV8xL2ZyYWc6ODVkYmExZWRmOTM0NDBlOTlmNjU5NDhmYTdkOGZkOTMvdGV4dHJlZ2lvbjo4NWRiYTFlZGY5MzQ0MGU5OWY2NTk0OGZhN2Q4ZmQ5M18xNjI5_aad944e4-153c-4131-8231-ccff0368880c">341-6100</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="i1dbad092e05447cbbaec99507aa54883_D20230501-20230501"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0MzYzZjQxZWU2YjQ3MmE5Nzc3YzNiNjZiY2ZhMjZhL3NlYzo4NDM2M2Y0MWVlNmI0NzJhOTc3N2MzYjY2YmNmYTI2YV8xL2ZyYWc6ODVkYmExZWRmOTM0NDBlOTlmNjU5NDhmYTdkOGZkOTMvdGV4dHJlZ2lvbjo4NWRiYTFlZGY5MzQ0MGU5OWY2NTk0OGZhN2Q4ZmQ5M18xNjMw_b955b7d4-5b0e-4d3a-b00b-759d35885d0f">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="i1dbad092e05447cbbaec99507aa54883_D20230501-20230501"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0MzYzZjQxZWU2YjQ3MmE5Nzc3YzNiNjZiY2ZhMjZhL3NlYzo4NDM2M2Y0MWVlNmI0NzJhOTc3N2MzYjY2YmNmYTI2YV8xL2ZyYWc6ODVkYmExZWRmOTM0NDBlOTlmNjU5NDhmYTdkOGZkOTMvdGV4dHJlZ2lvbjo4NWRiYTFlZGY5MzQ0MGU5OWY2NTk0OGZhN2Q4ZmQ5M18xNjI0_e04f45c5-c611-4f63-87c6-01b1ebc0f4a8">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="i1dbad092e05447cbbaec99507aa54883_D20230501-20230501"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0MzYzZjQxZWU2YjQ3MmE5Nzc3YzNiNjZiY2ZhMjZhL3NlYzo4NDM2M2Y0MWVlNmI0NzJhOTc3N2MzYjY2YmNmYTI2YV8xL2ZyYWc6ODVkYmExZWRmOTM0NDBlOTlmNjU5NDhmYTdkOGZkOTMvdGV4dHJlZ2lvbjo4NWRiYTFlZGY5MzQ0MGU5OWY2NTk0OGZhN2Q4ZmQ5M18xNjIy_90b62d63-d6ca-4979-88fe-72e3818e4202">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="i1dbad092e05447cbbaec99507aa54883_D20230501-20230501"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0MzYzZjQxZWU2YjQ3MmE5Nzc3YzNiNjZiY2ZhMjZhL3NlYzo4NDM2M2Y0MWVlNmI0NzJhOTc3N2MzYjY2YmNmYTI2YV8xL2ZyYWc6ODVkYmExZWRmOTM0NDBlOTlmNjU5NDhmYTdkOGZkOTMvdGV4dHJlZ2lvbjo4NWRiYTFlZGY5MzQ0MGU5OWY2NTk0OGZhN2Q4ZmQ5M18xNjI1_87dcab12-fcf8-4dda-92fc-a45d3c737230">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="i1dbad092e05447cbbaec99507aa54883_D20230501-20230501"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0MzYzZjQxZWU2YjQ3MmE5Nzc3YzNiNjZiY2ZhMjZhL3NlYzo4NDM2M2Y0MWVlNmI0NzJhOTc3N2MzYjY2YmNmYTI2YV8xL2ZyYWc6ODVkYmExZWRmOTM0NDBlOTlmNjU5NDhmYTdkOGZkOTMvdGFibGU6YjEwMGYxMzIyMjNjNGIxM2FlNDFiNWZjZjg2ODlhMDkvdGFibGVyYW5nZTpiMTAwZjEzMjIyM2M0YjEzYWU0MWI1ZmNmODY4OWEwOV8yLTAtMS0xLTE1NDUxMA_dd44f1ef-748f-472d-8ff7-94455fd7c527">Common Stock, $0.01 Par Value Per Share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i1dbad092e05447cbbaec99507aa54883_D20230501-20230501"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0MzYzZjQxZWU2YjQ3MmE5Nzc3YzNiNjZiY2ZhMjZhL3NlYzo4NDM2M2Y0MWVlNmI0NzJhOTc3N2MzYjY2YmNmYTI2YV8xL2ZyYWc6ODVkYmExZWRmOTM0NDBlOTlmNjU5NDhmYTdkOGZkOTMvdGFibGU6YjEwMGYxMzIyMjNjNGIxM2FlNDFiNWZjZjg2ODlhMDkvdGFibGVyYW5nZTpiMTAwZjEzMjIyM2M0YjEzYWU0MWI1ZmNmODY4OWEwOV8yLTItMS0xLTE1NDUxMA_f54e6ab4-149b-45c0-9716-58c5adb4edbf">VRTX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i1dbad092e05447cbbaec99507aa54883_D20230501-20230501"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0MzYzZjQxZWU2YjQ3MmE5Nzc3YzNiNjZiY2ZhMjZhL3NlYzo4NDM2M2Y0MWVlNmI0NzJhOTc3N2MzYjY2YmNmYTI2YV8xL2ZyYWc6ODVkYmExZWRmOTM0NDBlOTlmNjU5NDhmYTdkOGZkOTMvdGFibGU6YjEwMGYxMzIyMjNjNGIxM2FlNDFiNWZjZjg2ODlhMDkvdGFibGVyYW5nZTpiMTAwZjEzMjIyM2M0YjEzYWU0MWI1ZmNmODY4OWEwOV8yLTQtMS0xLTE1NDUxMA_219a22bd-9985-400f-aaee-3e45313e4792">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="i1dbad092e05447cbbaec99507aa54883_D20230501-20230501"
      id="id3VybDovL2RvY3MudjEvZG9jOjg0MzYzZjQxZWU2YjQ3MmE5Nzc3YzNiNjZiY2ZhMjZhL3NlYzo4NDM2M2Y0MWVlNmI0NzJhOTc3N2MzYjY2YmNmYTI2YV8xL2ZyYWc6ODVkYmExZWRmOTM0NDBlOTlmNjU5NDhmYTdkOGZkOTMvdGV4dHJlZ2lvbjo4NWRiYTFlZGY5MzQ0MGU5OWY2NTk0OGZhN2Q4ZmQ5M18xNjIz_9066ae31-51b0-455f-b0f6-05a44cf89397">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>8
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M8-IZNR?>#HQ*BWWH7!G8U1:'*\[@4; 7P/F%4F8_L%O;\I>)_K]02P,$%
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M$MP>:4#M.*2VBZD8_1!2:5K5N %(MB6/:<Z10J[4+!XUA]) 1-MC0[!:+#Y
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M2:AU[D&P]_ :C1W-CQ^W_ %02P,$%     @ #(&A5B0>FZ*M    ^ $  !H
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M_0QI-^2!8ECFS_A[QA?_&\[Q$<+NOS^QO-9.&G_FB^$_7G\!4$L! A0#%
M  @ #(&A5@=!36*!    L0   !               ( !     &1O8U!R;W!S
M+V%P<"YX;6Q02P$"% ,4    "  ,@:%68;,3G>\    K @  $0
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M<R\N<F5L<U!+ 0(4 Q0    (  R!H58<.&7J/P$  #P"   /
M  "  680  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    "  ,@:%6)!Z;HJT
M  #X 0  &@              @ '2$0  >&PO7W)E;',O=V]R:V)O;VLN>&UL
M+G)E;'-02P$"% ,4    "  ,@:%699!YDAD!  #/ P  $P
M@ &W$@  6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     "0 ) #X"   !%
"   !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="vrtx-20230501.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Document and Entity Information Document</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vrtx.com/role/DocumentandEntityInformationDocument</Role>
      <ShortName>Document and Entity Information Document</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 1 fact(s) appearing in ix:hidden were eligible for transformation: dei:EntityRegistrantName -  vrtx-20230501.htm 4</Log>
  </Logs>
  <InputFiles>
    <File doctype="8-K" original="vrtx-20230501.htm">vrtx-20230501.htm</File>
    <File>ex-991_q12023.htm</File>
    <File>vrtx-20230501.xsd</File>
    <File>vrtx-20230501_lab.xml</File>
    <File>vrtx-20230501_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "vrtx-20230501.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2022": 22
   },
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "vrtx-20230501.htm"
     ]
    },
    "labelLink": {
     "local": [
      "vrtx-20230501_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "vrtx-20230501_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "vrtx-20230501.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 23,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 3,
    "total": 3
   },
   "keyCustom": 0,
   "keyStandard": 22,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "vrtx",
   "nsuri": "http://www.vrtx.com/20230501",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrtx-20230501.htm",
      "contextRef": "i1dbad092e05447cbbaec99507aa54883_D20230501-20230501",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Document and Entity Information Document",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.vrtx.com/role/DocumentandEntityInformationDocument",
     "shortName": "Document and Entity Information Document",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrtx-20230501.htm",
      "contextRef": "i1dbad092e05447cbbaec99507aa54883_D20230501-20230501",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vrtx.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vrtx.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vrtx.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vrtx.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vrtx.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vrtx.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vrtx.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vrtx.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vrtx.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vrtx.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vrtx.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vrtx.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vrtx.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vrtx.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vrtx.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer",
        "terseLabel": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vrtx.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer",
        "terseLabel": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vrtx.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vrtx.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vrtx.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vrtx.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vrtx.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vrtx.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0000875320-23-000010-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000875320-23-000010-xbrl.zip
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M*.KF%: L"<"%V3'+!_1WV&!*MVOV&7DAOR5ZCK6YG]ZVNL?XZ?KB"Y)H0E-
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M!8D5"F;04\/(1_8$["WD$BQH$MV^$FYTIP8&@H!;_XD4@PUVA('EQ+,C4#
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M%S>R+1:,L?^!$TO )#W.5R)%ZUV9R5!].:X_EDZ)IDCJ#SR061^6X$<!=0\
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M@NJ]COI ACH'@JA%Z2 H/P)*3XRS6S)"WHQ\G71[>J.PY^0T(=:\'I-IX;Y
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M&DX8-7=TLFJ$F  ;A)@,T/*P$:=H&^\EH3WEWU+VZXI9*1[L6.F 3Y\GM99
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M77B<6:@M@;,'S^:..CQG*4868T& );GC?38[@\5XRBX<%HX%_.\+P4!2A>.
M"0"LQ?+MO0FXV-JZPGYZVVP=WV )N/6?* BQ#4I O^%)L':$S^*0(@CEA$X(
MT ?$AOQ!8'=.FWX,7>;$)\=G!L+?\6EX GCV].> >3XVP7^(1Z'V*P^F" (J
M0Q\(1PQEF!LW"%WSMCK@@3J)%O,2"2%JA4>(!B$$VR9&W #P+3D<"E]@"'8@
MPGLAG.R>_/3VJ&%TCP,VC&R;307W%8; Y0$,9S':TVM B:/CTPKKFV".8]>
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MA.J0KMYZ#JN*')$8L2#P@,KAGA."F52O_Q->C[?6\$\"SLBS> PSN,F&23A
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MG7#0S-.^5S;T@9&=G-]< R^T\.1Z%][&;=C-"FP$[ 2Y@S/0J>3D$#KLM4(
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M"<0+?UZ$$S-2>"J'3"6_N*B^D,L(TW%2%XEV!%2RP)7 %4T5.();T/MC)]2
MX%)VGRUHT$5&OI[YO$E.,0]@4&JF,8)9(,*G*N=FR8YKK*!KV3<FJA'!9\X^
M#.+4!^F#;@0ZI!3S4,WOUB+-)9E&$'FHM".VH7M?V3WH\XU\(L\95HP32]6X
M-&I&JB0!"U?H..@6SJ"A#K4'?"C0L!;HP^>@Z"'^T&M0VFF7&SZ3@<<";\,<
MD"51*0R'C#IY:7KJJ&)(Z&@7EJ): A%&+!#AT-7>J!]?PUWHWD82H9\,REI)
M?.:PK(C0A@!&_I)H$(B_(H2-CGQ0* &O!^A=R":J9)RD*@W4!&H!)1/S[V5
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MC#F[XE+-K]<QJL91KU=D0E$SE[X;V$#R[!)X(!A>6?@VVP5!T4O,<BH45B9
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M(2ODW8O7=^!BE?+WC,N7DV_]/U!+ P04    "  ,@:%6)HBM07X"  ##!P
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M GH]'^#_Y,D 1W\DP)$>!C"&QP"X/0# Y:?_F]_$N3XZ?;%^)5T^>_STQ?\
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M:.]QHOUHW[$_VOL/4$L! A0#%     @ #(&A5E'J<4M00   T+P" !$
M         ( !     &5X+3DY,5]Q,3(P,C,N:'1M4$L! A0#%     @ #(&A
M5J>Y;9EY%   E7\  !$              ( !?T   '9R='@M,C R,S U,#$N
M:'1M4$L! A0#%     @ #(&A5B:(K4%^ @  PP<  !$              ( !
M)U4  '9R='@M,C R,S U,#$N>'-D4$L! A0#%     @ #(&A5O7-O]YI"@
M25X  !4              ( !U%<  '9R='@M,C R,S U,#%?;&%B+GAM;%!+
M 0(4 Q0    (  R!H590CG[QM 8  #$Q   5              "  7!B  !V
J<G1X+3(P,C,P-3 Q7W!R92YX;6Q02P4&      4 !0!# 0  5VD

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
